Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Prostate Cancer Foundation
Phase I/II Trials of Anti-Androgen Drugs Show Promise for Patients with Advanced Prostate Cancer
April 21st, 2009
In a paper published online this week in Science Express (the online version of Science magazine), researchers report that early clinical trials for two compounds, MDV3100 and RD162, show initial promise for patients suffering from an advanced metastatic form of the disease known as castration-resistant prostate cancer. MDV3100, designed to work by antagonizing androgen receptor action and preventing testosterone from fueling tumor growth, reduced PSA levels in 43 percent of patients by more than 50 percent. These compounds were initially derived through work funded by a Prostate Cancer Foundation (PCF) Competitive Award granted to Drs. Owen Witte, Charles Sawyers and...
Source: Cancer Weekly (2009-04-21)
|
